S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
66,000% upside on tiny biotech? (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
Final stage before digital money (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Final stage before digital money (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
66,000% upside on tiny biotech? (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
Final stage before digital money (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Final stage before digital money (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
66,000% upside on tiny biotech? (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
Final stage before digital money (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Final stage before digital money (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
66,000% upside on tiny biotech? (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
Final stage before digital money (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Final stage before digital money (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
NYSE:HAE

Haemonetics (HAE) Competitors

$83.21
+0.33 (+0.40%)
(As of 05/26/2023 ET)
Compare
Today's Range
$82.98
▼
$84.00
50-Day Range
$76.08
▼
$89.45
52-Week Range
$58.23
▼
$91.39
Volume
201,256 shs
Average Volume
319,205 shs
Market Capitalization
$4.21 billion
P/E Ratio
37.31
Dividend Yield
N/A
Price Target
$103.17
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

HAE vs. ICUI, MMSI, IRTC, NARI, IART, GKOS, GMED, AXNX, ATRC, and NUVA

Should you be buying Haemonetics stock or one of its competitors? The main competitors of Haemonetics include ICU Medical (ICUI), Merit Medical Systems (MMSI), iRhythm Technologies (IRTC), Inari Medical (NARI), Integra LifeSciences (IART), Glaukos (GKOS), Globus Medical (GMED), Axonics (AXNX), AtriCure (ATRC), and NuVasive (NUVA). These companies are all part of the "surgical & medical instruments" industry.

Haemonetics vs.

ICU Medical (NASDAQ:ICUI) and Haemonetics (NYSE:HAE) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation, community ranking and dividends.

ICU Medical has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500.

93.9% of ICU Medical shares are owned by institutional investors. 7.5% of ICU Medical shares are owned by company insiders. Comparatively, 1.7% of Haemonetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ICU Medical received 16 more outperform votes than Haemonetics when rated by MarketBeat users. Likewise, 64.63% of users gave ICU Medical an outperform vote while only 60.17% of users gave Haemonetics an outperform vote.

CompanyUnderperformOutperform
ICU MedicalOutperform Votes
380
64.63%
Underperform Votes
208
35.37%
HaemoneticsOutperform Votes
364
60.17%
Underperform Votes
241
39.83%

In the previous week, Haemonetics had 7 more articles in the media than ICU Medical. MarketBeat recorded 11 mentions for Haemonetics and 4 mentions for ICU Medical. Haemonetics' average media sentiment score of 1.05 beat ICU Medical's score of 1.03 indicating that Haemonetics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ICU Medical
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Haemonetics
4 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

ICU Medical presently has a consensus target price of $203.00, suggesting a potential upside of 17.18%. Haemonetics has a consensus target price of $103.17, suggesting a potential upside of 23.98%. Given Haemonetics' stronger consensus rating and higher probable upside, analysts clearly believe Haemonetics is more favorable than ICU Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ICU Medical
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Haemonetics
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.67

Haemonetics has a net margin of 9.87% compared to ICU Medical's net margin of -2.00%. Haemonetics' return on equity of 20.13% beat ICU Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
ICU Medical -2.00% 6.42% 2.95%
Haemonetics 9.87% 20.13% 8.31%

Haemonetics has lower revenue, but higher earnings than ICU Medical. ICU Medical is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ICU Medical$2.28 billion1.83-$74.29 million-$1.92-90.23
Haemonetics$1.17 billion3.60$115.40 million$2.2337.31

Summary

Haemonetics beats ICU Medical on 12 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HAE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HAE vs. The Competition

Export to Excel
MetricHaemoneticsSurgical & medical instruments IndustryMedical SectorNYSE Exchange
Market Cap$4.21B$3.55B$4.57B$14.55B
Dividend YieldN/A2.93%2.32%4.07%
P/E Ratio37.3143.11113.1020.59
Price / Sales3.6028.043,697.958.98
Price / Cash16.7365.5298.1623.16
Price / Book5.145.395.049.08
Net Income$115.40M$59.73M$118.58M$897.96M
7 Day Performance-1.08%-2.79%1.10%1.43%
1 Month Performance-0.60%-1.53%1.28%-1.75%
1 Year Performance29.69%-12.57%19.56%-10.31%

Haemonetics Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ICUI
ICU Medical
2.1222 of 5 stars		$184.93
-3.6%		$203.00
+9.8%		-5.1%$4.45B$2.31B-96.3214,500
MMSI
Merit Medical Systems
2.4629 of 5 stars		$80.66
-4.5%		$83.43
+3.4%		+30.3%$4.85B$1.17B54.506,846Positive News
IRTC
iRhythm Technologies
2.0306 of 5 stars		$126.40
-2.8%		$154.40
+22.2%		-15.2%$3.85B$410.92M-36.431,793
NARI
Inari Medical
2.0596 of 5 stars		$62.23
-2.2%		$89.11
+43.2%		-12.6%$3.56B$383.47M-117.421,100Short Interest ↑
IART
Integra LifeSciences
2.6591 of 5 stars		$40.48
-20.2%		$52.50
+29.7%		-38.1%$3.32B$1.56B19.653,722Analyst Report
Short Interest ↓
News Coverage
High Trading Volume
GKOS
Glaukos
1.351 of 5 stars		$58.26
-1.8%		$56.13
-3.7%		+31.9%$2.86B$289.08M-19.95727Short Interest ↑
GMED
Globus Medical
2.5335 of 5 stars		$54.71
-3.8%		$70.50
+28.9%		-20.8%$5.49B$759.12M27.772,600Short Interest ↑
AXNX
Axonics
2.314 of 5 stars		$51.57
-0.1%		$78.88
+52.9%		-7.2%$2.60B$273.70M-52.09517Analyst Report
Positive News
ATRC
AtriCure
2.1732 of 5 stars		$48.13
-2.4%		$59.83
+24.3%		+11.5%$2.27B$330.38M-58.701,050
NUVA
NuVasive
2.1892 of 5 stars		$38.68
-3.9%		$50.98
+31.8%		-35.0%$2.11B$1.22B113.773,000Short Interest ↑

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NYSE:HAE) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -